NEW YORK (GenomeWeb News) – Mediomics has reeled in a $997,251 grant from the National Cancer Institute to continue developing technologies for monitoring the titer and quality of recombinant biologics, the company said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.